Guided Therapeutics Inc. (OTCMKTS:GTHP) Sees Large Drop in Short Interest

Guided Therapeutics Inc. (OTCMKTS:GTHP) saw a large decline in short interest in December. As of December 15th, there was short interest totaling 1,846 shares, a decline of 28.4% from the November 30th total of 2,580 shares. Based on an average daily trading volume, of 13,148 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 13,148 shares, the short-interest ratio is currently 0.1 days.

Guided Therapeutics Price Performance

OTCMKTS:GTHP traded up $0.01 during trading hours on Monday, hitting $0.37. The company’s stock had a trading volume of 6,444 shares, compared to its average volume of 13,568. The company has a market capitalization of $32.19 million, a P/E ratio of -7.49 and a beta of 0.64. Guided Therapeutics has a twelve month low of $0.06 and a twelve month high of $0.47. The stock has a fifty day simple moving average of $0.26 and a 200-day simple moving average of $0.25.

Guided Therapeutics (OTCMKTS:GTHP) last posted its earnings results on Thursday, November 13th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $0.06 million for the quarter.

About Guided Therapeutics

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.